Diagnosing Alzheimer’s disease today may require painful and expensive procedures, such as a spinal tap to remove cerebral spinal fluid or a PET scan that costs between $5,000 and $10,000 (for which Medicare does not pay). A technology platform and Alzheimer’s diagnostic being developed by precision neurology company Altoida Inc. has the potential to eliminate all that.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,